Reading Time: < 1 minute Cergentis, a genomics company that develops and commercializes kits and services based on its proprietary Targeted Locus Amplification (TLA) technology, announced the completion of a successful analytical validation study in lymphoma to show the benefits of TLA for the detection of clinically relevant translocations in tumor biopsies. The results of this study, performed in collaboration with researchers from Hubrecht Institute and lymphoma experts of 5 Dutch pathology labs (UMCU, Amsterdam UMC, UMCG, LUMC, and LabPON), have now been published in Nature Communications. The FFPE-TLC approach promises to revolutionize lymphoma diagnostics and…
Read MoreRevolutionizing Cancer Diagnostics
